Did you know? You can suggest edits to improve this peptide information.
Overview
What is Tirzepatide?
Tirzepatide is a revolutionary dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. FDA-approved for both type 2 diabetes management and chronic weight management, it has demonstrated unprecedented efficacy for weight loss and metabolic health optimization. Tirzepatide works by mimicking incretin hormones that regulate blood sugar, slow gastric emptying, and reduce appetite, offering superior results compared to single-mechanism GLP-1 agonists.
Key Benefits
Dramatic weight loss (15-22% body weight), superior diabetes control, reduced cardiovascular risk, improved insulin sensitivity, appetite suppression, preserved muscle mass
Mechanism of Action
Dual agonist of GIP and GLP-1 receptors, glucose-dependent insulin stimulation, gastric emptying delay, glucagon suppression, central satiety signaling through hypothalamic pathways
Molecular Information
Weight
4,813.55 Da
Length
39 amino acids
Type
Dual GLP-1/GIP agonist
Amino Acid Sequence:
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-Gly-Gly-Gly-Gly-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys
* C20 fatty diacid conjugation for once-weekly dosing
Pharmacokinetics
Research Indications
Severe Obesity Management
Clinical trials demonstrate 15-22% body weight reduction in non-diabetic obese individuals - superior to all existing weight loss medications including semaglutide
Metabolic Syndrome Reversal
Comprehensive improvement in waist circumference, blood pressure, triglycerides, HDL cholesterol, and insulin resistance markers
Body Composition Optimization
Preferentially reduces visceral adipose tissue while preserving lean muscle mass when combined with resistance training and adequate protein
Research Protocols
Disclaimer
These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.
Timing
Tirzepatide can be injected at any time of day, with or without food. Choose a consistent day of the week for weekly injections to maintain steady levels.
Peptide Interactions
How to Reconstitute
Important
Always use bacteriostatic water (BAC). Sterile technique is essential.
Remove tirzepatide vial from refrigerator and allow to reach room temperature for 15-20 minutes to prevent condensation
Clean vial tops with alcohol wipes using circular motion from center outward, allow to air dry completely
Calculate appropriate reconstitution volume based on desired concentration using the calculator below
Draw calculated amount of bacteriostatic water into insulin syringe, ensuring no air bubbles
Insert needle into tirzepatide vial at 45-degree angle against the glass wall, NOT directly into powder
Slowly inject BAC water down the side of the vial - inject drop by drop to avoid foaming or protein degradation
Remove needle and gently swirl vial in circular motion - NEVER shake vigorously as this destroys the protein
Allow solution to sit for 2-3 minutes if any cloudiness persists, then swirl gently again until completely clear
Final solution should be completely clear and colorless - any persistent cloudiness indicates degradation
Label vial with reconstitution date and concentration, store in refrigerator at 2-8°C immediately
Use within 28 days of reconstitution, always use fresh needle for each injection, inspect for particles before use
Quality Indicators
White to off-white lyophilized powder
Properly freeze-dried tirzepatide appears as light, fluffy powder cake without clumping
Clear reconstituted solution
Should be completely clear and colorless after proper reconstitution - no particles or cloudiness
Intact vial seal and proper labeling
Rubber stopper should be intact, clear mg dosage labeling, batch numbers, and expiration dates visible
Proper storage maintenance
Stored at correct temperature (2-8°C), protected from light, never frozen or overheated
Clumping, discoloration, or moisture
Powder should not be clumped, yellow/brown colored, or show signs of moisture damage or melting
Persistent cloudiness after reconstitution
Cloudiness that doesn't clear after proper mixing indicates protein aggregation or contamination
Unusual crystallization patterns
Large crystals or unusual formations may indicate storage temperature fluctuations or degradation
What to Expect
- Appetite reduction within 1-3 days of first injection
- Mild to moderate nausea for first 2-4 weeks (typically improves significantly)
- 1-3 lbs weight loss per week during active weight loss phase
- Improved blood sugar control within 1-2 weeks for diabetics
- Dramatically reduced food cravings and smaller portion satisfaction
- Better satiety and meal satisfaction lasting 6-7 days per injection
- Possible fatigue during initial adaptation weeks
- Peak weight loss effects typically seen at 16-24 weeks
- Improved energy levels after initial adaptation period
Side Effects & Safety
- Start with lowest dose (2.5mg) and escalate gradually every 4 weeks to minimize side effects
- Contraindicated with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
- Monitor for signs of acute pancreatitis (severe, persistent abdominal pain radiating to the back)
- Significant nausea is common initially but typically improves - stay hydrated and eat smaller meals
- Requires prescription and medical supervision - not available over-the-counter
- Store in refrigerator between 2-8°C, never freeze or shake vigorously
- May require adjustment of other diabetes medications to prevent hypoglycemia
References
SURMOUNT-2 T2DM Trial (2023)
15mg dose achieved 15.7% weight loss with significant improvements in all cardiometabolic parameters
SURPASS-CVOT Cardiovascular Outcomes (2023)
26% reduction in major adverse cardiovascular events, establishing cardioprotective benefits
SURMOUNT-1 Phase 3 Trial (2022)
15mg weekly dose achieved 22.5% weight loss vs 2.4% placebo - largest weight loss seen in pharmaceutical trials
Quick Start Guide
Community Poll
Question 1 of 10
What is your experience with this compound?
Poll Results
Loading results...
Community Insights
Self-reported by PepPedia users. Not clinical evidence. Health changes reflect all users, including those taking multiple compounds.
Was this helpful?
Your feedback helps us improve PepPedia